Prolonged progression free survival does not relate to quality of response to treatment with thalidomide in patients with relapsed multiple myeloma (MM)

被引：0
|
作者：
Quach, Hang [1 ]
Prince, Miles H. [1 ]
Mileshkin, Linda [1 ]
Seymour, John F. [1 ]
Westerman, David [1 ,2 ]
Milner, Alvin D. [3 ]
机构：
[1] Peter MacCallum Canc Ctr, Div Haematol & Med Oncol, Melbourne, Vic, Australia
[2] Peter MacCallum Canc Ctr, Dept Pathol, Melbourne, Vic, Australia
[3] Peter MacCallum Canc Ctr, Ctr Biostat & Clin Trials, Melbourne, Vic, Australia
来源：
BLOOD | 2007年 / 110卷 / 11期
关键词：
D O I：
10.1182/blood.V110.11.2718.2718
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
2718
引用
收藏
页码：798A / 798A
页数：1
相关论文
共 50 条
  • [11] PROGRESSION-FREE SURVIVAL AS A SURROGATE ENDPOINT FOR OVERALL SURVIVAL IN PATIENTS WITH RELAPSED OR REFRACTORY MULTIPLE MYELOMA
    Dimopoulos, M.
    Sonneveld, P.
    Nahi, H.
    Kumar, S.
    Hashim, M.
    Kulakova, M.
    Duran, M.
    Heeg, B.
    Lam, A.
    Dearden, L.
    VALUE IN HEALTH, 2017, 20 (09) : A408 - A408
  • [12] How Does Treatment Intolerance Affect Survival in Patients with Multiple Myeloma (MM)?
    Alomran, Maryam
    Wellard, Cameron
    Chen, Pin-Yen
    Moore, Elizabeth M.
    Chng, Wee Joo
    BLOOD, 2022, 140 : 10075 - 10076
  • [13] Thalidomide maintenance treatment increases progression-free but not overall survival in elderly patients with myeloma
    Ludwig, Heinz
    Adam, Zdenek
    Tothova, Elena
    Hajek, Roman
    Labar, Boris
    Egyed, Miklos
    Spicka, Ivan
    Gisslinger, Heinz
    Drach, Johannes
    Kuhn, Ingrid
    Hinke, Axel
    Zojer, Niklas
    HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2010, 95 (09): : 1548 - 1554
  • [14] Thalidomide As Maintenance Therapy in Multiple Myeloma (MM) Improves Progression Free Survival (PFS) and Overall Survival (OS): A Meta-Analysis
    Nooka, Ajay K.
    Behera, Madhusmita
    Boise, Lawrence H.
    Watson, Melanie
    Kaufman, Jonathan L.
    Lonial, Sagar
    BLOOD, 2011, 118 (21) : 807 - 808
  • [15] Impact of lenalidomide dose on progression-free survival in patients with relapsed or refractory multiple myeloma
    M A Dimopoulos
    M Hussein
    A S Swern
    D Weber
    Leukemia, 2011, 25 : 1620 - 1626
  • [16] Impact of lenalidomide dose on progression-free survival in patients with relapsed or refractory multiple myeloma
    Dimopoulos, M. A.
    Hussein, M.
    Swern, A. S.
    Weber, D.
    LEUKEMIA, 2011, 25 (10) : 1620 - 1626
  • [17] Thalidomide treatment of relapsed multiple myeloma patients and changes in circulating VEGF and bFGF
    Pitini, V
    Teti, D
    Arrigo, C
    Aloi, G
    BRITISH JOURNAL OF HAEMATOLOGY, 2002, 119 (01) : 275 - 275
  • [18] Response to a combination therapy of thalidomide and Pegintron® in patients with progressive multiple myeloma (MM).
    Kasper, B
    Moehler, TM
    Neben, K
    Ho, AD
    Goldschmidt, H
    BLOOD, 2001, 98 (11) : 309B - 309B
  • [19] TREATMENT RESPONSE IN RELAPSED AND REFRACTORY MULTIPLE MYELOMA PATIENTS
    Ioana, I.
    Liviu, C.
    Maria, C.
    Claudiu, I.
    Maria, I.
    Mihai, I.
    Dacian, O.
    Ovidiu, P.
    Cristina, S.
    Despina, C.
    Hortensia, I.
    HAEMATOLOGICA, 2013, 98 : 614 - 614
  • [20] Quality of life (QOL) assessment in patients with relapsed/refractory multiple myeloma (MM) treated with thalidomide (T) plus celecoxib (Cxb).
    Mileshkin, LR
    Roberts, A
    Ganju, V
    Underhill, C
    Catalano, J
    Bell, R
    Lillie, K
    Milner, AD
    Zeldis, JB
    Prince, HM
    JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (16) : 786S - 786S
12345